SCHEMBL1702950

SCHEMBL1702950

Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(N)c34)cc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.74
KIT P10721 15/20 0.74
FLT3 P36888 13/20 0.74
FLT1 P17948 4/20 0.74
FLT4 P35916 3/20 0.74
LCK P06239 3/20 0.74
CSF1R P07333 3/20 0.74
PLK4 O00444 2/20 0.74
AURKA O14965 2/20 0.74
ROCK2 O75116 2/20 0.74
RPS6KA5 O75582 2/20 0.74
RPS6KA4 O75676 2/20 0.74
PRKD3 O94806 2/20 0.74
MAP4K4 O95819 2/20 0.74
RET P07949 2/20 0.74
MET P08581 2/20 0.74
FGFR1 P11362 2/20 0.74
RPS6KB1 P23443 2/20 0.74
AXL P30530 2/20 0.74
FRK P42685 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703272 0.90 KDR (0.72) KDRKITFLT3FLT1FLT4
SCHEMBL1703315 0.89 KDR (0.70) KDRKITFLT3FLT1FLT4
SCHEMBL2818366 0.88 KDR (0.69) KDRKITFLT3FLT1FLT4
SCHEMBL1703080 0.88 KDR (0.74) KDRKITFLT3FLT1FLT4
SCHEMBL2236770 0.87 KDR (0.60) KDRKITFLT3FLT1FLT4
SCHEMBL1702941 0.87 KDR (0.75) KDRKITFLT3FLT1FLT4
SCHEMBL2237890 0.87 KDR (0.75) KDRKITFLT3FLT1FLT4
SCHEMBL419365 0.85 KDR (1.00) KDRKITFLT3FLT1FLT4
SCHEMBL1702977 0.85 KDR (0.75) KDRKITFLT3FLT1FLT4
SCHEMBL2235206 0.84 KDR (0.62) KDRKITFLT3FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20100004306-A1 PIGF-1 Assay and kits and components thereof ABBOTT LABORATORIES (US) 2010-01-07 US disclosed
US-20100004306-A1 PIGF-1 Assay and kits and components thereof ABBOTT LABORATORIES (US) 2010-01-07 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885FLT3 79/4885
US-20100004306-A1 PIGF-1 Assay and kits and components thereof PGF, FLT1, HDGF KDR 9/4885KIT 140/4885FLT3 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.